Lans Holdings Successfully Completes Due Diligence of Global Stem Cells Group
MIAMI, FL, July 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Lans Holdings Inc. is pleased to announce that it has successfully completed its due diligence as per the binding letter of intent to acquire 100% of Global Stem Cells Group Inc (GSCG).
“We are very pleased to have successfully completed our due diligence,” said Dave Christensen, CEO of Lans Holdings, “And we are looking forward to the closing of the acquisition.”
The company has engaged Fruci & Associates as its auditors as it moves forward to complete its audits and reviews of its financials to bring the company back to current status.
This press release should be read in conjunction with the 8K filed on July 29, 2019 on www.sec.gov
Lans Holdings Enters into Binding LOI to Acquire Global Stem Cells Group
MIAMI, FL, May 28, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Lans Holdings Inc. (OTCPink: LAHO) is pleased to announce that it has entered into a binding letter of intent to acquire 100% of Global Stem Cells Group Inc. (GSCG).
GSCG operates in the global stem cell market which is forecasted by Transparency Market Research to reach $270 billion dollars by 2025 of which roughly 40% or $100 billion will be derived from outside of North America and growing at a 13.8% compounded annual growth rate.
GSCG specializes in leading-edge stem cell research, patient application and physician training. The company licenses its name and intellectual property to physicians around the world and supplies them with necessary equipment and medical supplies to perform stem cell treatments. The company currently has one of the largest member clinic networks in the world spanning over 25 countries.
“We are very pleased to have entered into this binding LOI with Global Stem Cells Group,” said Dave Christensen, CEO of Lans Holdings Inc. “This transaction represents a significant opportunity for our company to enter the explosive field of Stem Cell technology with a proven and seasoned team and I look forward to working closely with GSCG to execute on their growth plans.”
“We are excited to join forces with Lans Holdings,” said Benito Novas, President and CEO of Global Stem Cells Group. “This union will allow us to have access to the capital markets to further fuel our growth as the global stem cells market enters into an accelerated expansion phase.”
About Lans Holdings Inc.
Lans Holdings offers payment solutions. The Company makes it easy for sellers to start selling, and buyers to buy with confidence. The Company plans to process credit card payments online. In time, the Company hopes to be known in the industry as a secure and reliable source of payment processing. With the Company's breadth of business structure experience and technology consultants, the Company aims to help projects and companies grow.
Further information on the Company can be found at www.sec.gov and the company's website at www.LansHoldings.com.
LAHO: Global Stem Cells Group Announces Opening of Two New Stem Cell Centers
Miami, FL, June 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Lans Holdings Inc. is pleased to announce that Global Stem Cells Group Inc. (GSCG) www.stemcellsgroup.com has opened two new stem cell offices, one in Valencia, Spain and one in Cochabamba, Bolivia. This brings the total number of global Stem Cell centers to 36 worldwide in 27 countries.
The new clinic in Valencia will be the group’s third operation in Spain and the fourth in Europe. The Global Stem Cells Group’s Valencia center joins the already existing centers in Spain, which include locations in Bruselas, Madrid, and Barcelona. In opening the new center, GSCG has signed an agreement with Dra. Caicedo, a specialist in hair loss treatment with an interest in delivering stem cell based treatments to her patients in Valencia.
The Cochabamba clinic will be the first of its kind outside of the US that will provide a comprehensive range of treatment options for patients suffering from degenerative conditions. Backed by Dra. Vargas and her team’s expertise, patients will have access to treatments via autologous stem cells, exosomes, and heterologous mesenchymal stem cells derived from umbilical cord blood. The center will feature a storage facility that meets the highest industry standards to be able to store exosomes and MSCs onsite, giving patients and doctors more convenient and faster access to critical treatment options.
Lans Holdings is currently working to bring all of its financials current and expects this to be completed and filed with the SEC within the next 90 days.
For more information on Global Stem Cells Group please visit: http://www.stemcellsgroup.com/
https://www.otcmarkets.com/stock/LAHO/security Lans Holdings, Inc.
Our Email is:-email@example.com
For further information, please contact:
Telephone: +1.786.786.5758 and 305-755-7451
Management is very good at responding. MEGA $LAHO DD-BREAKOUT to PENNIES Global Stem..Market to Reach US$ 467 billion by 2024 ..Due to the increased funding from Government and Private sector and rising global awareness.
..global stem cell therapy..average growth rate of 46.8%
The Shiller P/E is a more reasonable market valuation indicator than the P/E ratio because it eliminates fluctuation of the ratio caused by the variation of profit margins during business cycles.
Sector Healthcare: 30.50
Sector Technology: 34.40
BioTechnology ..One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025.. https://www.worldstemcellsummit.com/2019/05/09/human-lifespan-could-soon-pass-100-years-thanks-to-medical-tech-says-bank-of-america/
Pfizer and Allergan Merge in $160 Billion Deal to Become New Behemoth in the Drug World
What Does Pfizer Have to do with the World of Stem Cells?
Most people would not call Pfizer a stem cell company, much less a cell therapy company, a regenerative medicine company, or even a biotech company. Pfizer is viewed as a “classic and traditional” pharmaceutical company, best known for its blockbuster sales of drugs, such as Lipitor and Viagra. While Pfizer is largely a drug company, the company has expressed periodic interest in the stem cell sector.
PFIZER ACQUIRES A STEM-CELL THERAPY
But as the science of stem cells has advanced, drug companies are taking an interest.
Global Stem Cells Group and Adimarket to Represent Magellan in Latin America and Middle East. Global Stem Cells Group CEO Benito Novas is driven by his passion for helping physicians and scientists change the world through stem cell medicine. Dedicated to creating critical organizational systems that ensure success, he is an expert in the field of specialized marketing focused on Biotechnology, Life Sciences, and Healthcare development.
Global Stem Cells Group’s Benito Novas Announces Agreement with Clinica Planas
..The ongoing partnership will offer certification in regenerative medicine for European-based medical practitioners .
GSCG ISSCA Launch Dates.
•Santiago de Chile, Chile: September 5, 2019
•Bogota, Colombia: October 4, 2019
•Buenos Aires, Argentina: October 11, 2019
•Miami, Florida (in English): November 1, 2019
..GSCG Knee Osteoarthrithis, Mayo Clinic Stem cell arthritis!
Mayo Clinic uses stem cell therapy to treat arthritis in knee
On the immortality of stem cells
University of Cologne
Summary:Stem cells are considered to be immortal in culture and, therefore, of great interest for aging research. This immortality is regulated by increased proteostasis, which controls the quality of proteins. A team of researchers found a link between increased proteostasis and immortality of human embryonic stem cells
https://www.sciencedaily.com/releases/2018/03/180307101033.htm GSCG Office $121k per year, Top Location!!!
A Class “A” office building
Demographics Salary $95k